Reporting long-term effects of metabolic stress on human ovary carcinoma

A key challenge in cancer treatment is the wide range of cancer cells’ behavior towards chemotherapy and treatment procedures, which makes the outcomes of treatment often unpredictable, accompanied by cancer resistance and recurrence. One underlying reason is that tumor is a heterogeneous tissue. The cells within a tumor are at different metabolic states and hence behave differently from another and towards the chemotherapeutics. Many of the cells in the inner layers of a tumor lack an appropriate growth condition. However, upon tumor shrinkage, they can regrow and finally cause tumor resistance or recurrence. In the current study, for the first time, long term effects of different levels of metabolic stress on human ovary cancer cell line, A2780, is reported. In this in vitro model, the cells exposed to 10% serum were considered as control and metabolic stress was induced at 0.5, 0.25 and 0% serum for 1-6 days. In this 6-day period, cells’ morphology changes, size, cell cycle, mitochondrial function and protein content was measured at 24-hour intervals. Also, cells ability to recur was assessed with the above tests in a 24-hour release in 10% serum. The results of this study showed that A2780 cells show resistant features against metabolic stress and this longterm stress does not stop cells recurrence. These results indicate that in order to have a successful tumor treatment, a modified chemotherapy procedures against different types of cells laying within one tumor is required.

PDF

___

[1] Nakhjavani M, Zarghi A, Shirazi FH. Cytotoxicity of selected novel chalcone derivatives on human breast, lung and hepatic carcinoma cell lines. Iran J Pharm Res. 2014; 13(3): 953-958.

[2] Vakili N, Nakhjavani M, Mirzayi H, Shirazi F. Studying silibinin effect on human endothelial and hepatocarcinoma cell lines. Res Pharm Sci. 2012; 7(5): S174.

[3] Shirazi FH, Zarghi A, Kobarfard F, Zendehdel R, Nakhjavani M, Arfaiee S, Zebardast T, Mohebi S, Anjidani N, Ashtarinezhad A. Remarks in successful cellular investigations for fighting breast cancer using novel synthetic compounds. In: Gunduz M (Ed). Breast Cancer-Focusing Tumor Microenvironment, Stem cells and Metastasis, Croatia, InTech Europe, 2011, pp. 85-102.

[4] Sarafraz M, Hormozi F. Comparatively experimental study on the boiling thermal performance of metal oxide and multi-walled carbon nanotube nanofluids. Powder Technol. 2016; 287: 412-430.

[5] Sarafraz M, Hormozi F. Experimental investigation on the pool boiling heat transfer to aqueous multi-walled carbon nanotube nanofluids on the micro-finned surfaces. Int J Therm Sci. 2016; 100: 255-266.

[6] Sarafraz MM. Nucleate pool boiling of aqueous solution of citric acid on a smoothed horizontal cylinder. Heat Mass Transfer. 2012; 48(4): 611-619.

[7] Kamalgharibi M, Hormozi F, Zamzamian SAH, Sarafraz M. Experimental studies on the stability of CuO nanoparticles dispersed in different base fluids: influence of stirring, sonication and surface active agents. Heat Mass Transfer. 2016; 52(1): 55-62.

[8] Sarafraz M, Peyghambarzadeh S, Alavifazel S. Enhancement of nucleate pool boiling heat transfer to dilute binary mixtures using endothermic chemical reactions around the smoothed horizontal cylinder. Heat Mass Transfer. 2012; 48(10): 1755-1765.

[9] Sarafraz M. Experimental investigation on pool boiling heat transfer to formic acid, propanol and 2-butanol pure liquids under the atmospheric pressure. J Appl Fluid Mech. 2013; 6(1): 73-79.

[10] Sarafraz M, Arya A, Hormozi F, Nikkhah V. On the convective thermal performance of a CPU cooler working with liquid gallium and CuO/water nanofluid: A comparative study. Appl Therm Eng. 2017; 112: 1373-1381.

[11] Hoare M, Young AR, Narita M, editors. Autophagy in cancer: having your cake and eating it. Semin Cancer Biol; 2011; 21(6): 397-404.

[12] DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7(1): 11-20.

[13] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1): 57-70.

[14] Chisholm RH, Lorenzi T, Clairambault J. Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation. BBA-Gen Subjects. 2016; 1860(11): 2627-2645.

[15] Danhier P, Bański P, Payen VL, Grasso D, Ippolito L, Sonveaux P, Porporato PE. Cancer metabolism in space and time: Beyond the Warburg effect. BBA-Bioenergetics. 2017; 1858(8): 556-572.

[16] Hsieh JJ, Manley BJ, Khan N, Gao J, Carlo MI, Cheng EH, editors. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: a braided cancer river model of kidney cancer. Semin Cell Dev Bio; 2017; 64: 98-106.

[17] Ebrahim K, Vatanpour H, Zare A, Shirazi FH, Nakhjavani M. Anticancer activity a of Caspian cobra (Naja Naja oxiana) snake venom in human cancer cell lines via induction of apoptosis. Iran J Pharm Res. 2016; 15(Suppl): 101- 112.

[18] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA-Cancer J Clin. 2013; 63(1): 11-30.

[19] Chan J, Cheung M, Husain A, Teng N, West D, Whittemore A, Berek J, Osann K. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006; 108(3 Pt 1): 521-528.

[20] Nikounezhad N, Nakhjavani M, Shirazi FH. Cellular glutathione level does not predict ovarian cancer cells' resistance after initial or repeated exposure to cisplatin. J Exp Ther Oncol. 2017; 12(1): 1-7.

[21] Nakhjavani M, Nikounezhad N, Ashtarinezhad A, Shirazi FH. Human Lung Carcinoma Reaction against Metabolic Serum Deficiency Stress (Autumn 2016). Iran J Pharm Res. 2016; 15(4): 817-823.

[22] Nakhjavani M, Stewart DJ, Shirazi FH. Effect of steroid and serum starvation on a human breast cancer adenocarcinoma cell line. J Exp Ther Oncol. 2017; 12(1): 25-34.

[23] Pardee AB. G1 events and regulation of cell proliferation. Science. 1989; 246(4930): 603-608.

[24] Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006; 10(1): 51-64.

[25] Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, Thompson CB. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 2005; 120(2): 237-248.

[26] Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5): 703-707.

[27] Warburg O. On the origin of cancer. Science. 1956; 123(3191): 309-314.

[28] Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927; 8(6): 519-530.

[29] Bhutia YD, Babu E, Prasad PD, Ganapathy V. The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy. Asian J Pharm Sci. 2014; 9(6): 293-303.

[30] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930): 1029-1033.

[31] Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013; 15(6): 555-564.

[32] Jewell JL, Guan K-L. Nutrient signaling to mTOR and cell growth. Trends Biochem Sci. 2013; 38(5): 233-242.

[33] Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007; 117(2): 326-336.

[34] Liu D, Yang Y, Liu Q, Wang J. Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. Med Oncol. 2011; 28(1): 105-111.

[35] Qadir M, Kwok B, Dragowska W, To K, Le D, Bally M, Gorski SM. Macroautophagy inhibition sensitizes tamoxifenresistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Tr. 2008; 112(3): 389-403.

[36] Bao L, Jaramillo MC, Zhang Z, Zheng Y, Yao M, Zhang DD, Yi X. Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells. Mol Med Rep. 2015; 11(1): 91-98.

[37] Nikounezhad N, Nakhjavani M, Shirazi FH. Generation of cisplatin-resistant ovarian cancer cell lines. Iran J Pharm Sci. 2016; 12(1): 11-20.

[38] Rathmell JC, Vander Heiden MG, Harris MH, Frauwirth KA, Thompson CB. In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell. 2000; 6(3): 683- 692.

[39] Nakhjavani M, Ashtarinezhad A, Shirazi F. Studying the effect of methylparaben and propylparaben on growth curve of human breast adenocarcinoma cell line. Res Pharm Sci. 2012; 7(5): S175.

[40] Nakhjavani M, Nikounezhad N, H Shirazi F. Effects of Cells Density and Positioning on Optimized FTIR Biospectroscopy. Iran J Pharm Sci. 2014; 10(2): 61-68.

[41] Jamali B, Nakhjavani M, Hosseinzadeh L, Amidi S, Nikounezhad N, Shirazi FH. Intracellular GSH alterations and its relationship to level of resistance following exposure to cisplatin in cancer cells. Iran J Pharm Res. 2015; 14(2): 513- 519.

[42] Mathieu L, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2): 274-293.